NEW YORK, June 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Herpes Simplex Virus Treatment Industry
http://www.reportlinker.com/p0552782/Global-Herpes-Simplex-Virus-Treatment-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 38 companies including many key and niche players such as Agenus, Inc., AiCuris GmbH & Co.KG, Astellas Pharma, Inc., BioVex, Clinigen Group, Cytogenix, Inc., Genocea Biosciences, GlaxoSmithKline Plc, Lumavita AG, NanoBio Corporation, NanoViricides, Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, and Vical. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Prelude to Herpes Simplex Virus Infection II-1
Prevalence II-1
HSV Treatment II-1
Patent Expiries Of Select Leading HSV Therapeutics II-2
Leading HSV Drug (Valtrex) Sales Decline Due to Generic
Competition II-3
Table 1: Leading Drugs in the Global Herpes Simplex
Therapeutics Market (2007-2010): Value Sales for
Valtrex/Zelitrex, Zovirax in US$ Million (includes
corresponding Graph/Chart) II-3
Table 2: US Sales of Zovirax Products (2009 & 2010) in US$
Million II-4
Table 3: European Sales of Aldara (2008-2010) in US$ Million
(includes corresponding Graph/Chart) II-4
HSV2 Pipeline Analysis II-4
2. TREATMENT OF HERPES SIMPLEX VIRUS INFECTION II-6
Antiviral Treatment II-6
Major Drugs II-6
Valtrex (Valacyclovir) II-6
Table 4: Global Sales of Valtrex: 2002-2008 (includes
corresponding Graph/Chart) II-7
Zovirax (Acyclovir) II-7
Table 5: Global Sales Of Zovirax: 2002-2007 (includes
corresponding Graph/Chart) II-8
Famvir (Famciclovir) II-8
Foscarnet (Foscavir) II-9
Abreva (Docosanol) II-9
Cidofovir (Vistide) II-9
Denavir/ Vectavir (Penciclovir) II-9
Herpid II-9
Orajel Medicated Cold Sore Brush II-10
Viroxyn II-10
Vaccination II-10
Natural Treatment II-10
Other Treatment II-11
3. HSV VACCINES - AN INSIGHT II-12
List of Select Pipeline Therapeutic Vaccines for the Treatment
of HSV-2 II-12
Select Clinical Trials' Activity in the Herpes Simplex
Vaccines Space II-12
GSK to Discontinue Development of Simplirix™ II-12
GSK Initiates Phase III clinical Studies of Herpes Zoster
Vaccine II-12
Vical Presents Results from HSV-2 Vaccine Program II-13
BioVex Begins Phase I Clinical Trial for Immuno VEXHSV2 II-13
Acambis Begins Preclinical Testing of HSV Vaccine II-14
4. HERPES SIMPLEX VIRUS INFECTION - THE DISEASE, CAUSES, SYMPTOMS,
AND DIAGNOSIS II-15
Introduction II-15
Structure of Herpes Virus II-15
Biological Properties of Herpes Viruses II-15
Different Types of Human Herpes Viruses II-16
Latency in Herpes Virus Family II-16
Antibody Response II-17
HSV-1 and HSV-2 Infections II-17
Causes II-18
The Different Types of Herpes Infections II-18
Oral Herpes II-18
Transmission II-18
Symptoms II-19
Orolabial HSV Infections II-19
Recurrent Orolabial Herpetic Infection II-20
Genital Infections II-20
Primary Genital Infection II-20
Recurrent Genital Infection II-21
Recurrent Genital Infections in Males II-21
Recurrent Genital Infections in Females II-21
Prevention II-21
Diagnosis II-22
HSV CNS Infection II-22
Herpes Gladiatorum in Adolescent Wrestlers II-23
Acute Herpetic Infections II-23
Acute Herpetic Gingivostomatitis II-23
Acute Herpetic Pharyngotonsillitis II-24
HSV Infection in Neonates II-24
Disseminated HSV Disease II-25
Other HSV Infections II-25
Herpes Whitlow II-25
Primary Eye HSV Infection II-26
HSV Infections In Different Age Groups II-26
HSV Infection in Pregnant Women II-26
HSV in Immunocompromised Patients II-27
Morbidity and Mortality II-28
Seriousness of Herpes Simplex Infection II-28
Preventive Measures II-28
Diagnosis of HSV Infection II-29
Virologic Tests II-29
Tzanck Smear Test II-29
Polymerase Chain Reaction Tests II-30
Serologic Tests II-30
Biokit HSV-2 II-30
HerpeSelect II-30
Western Blot Test II-31
Type-Specific Assays Test II-31
Tests for Herpes Encephalitis II-31
Imaging Tests II-31
Brain Biopsy II-31
PCR II-31
5. PIPELINE ANALYSIS II-32
VivaGel Vaginal Microbicide II-32
VivaGel® Retains Anti-viral Activity Against HSV and HIV II-32
Simplivir™ II-32
HerpeCide II-33
NB-001 II-33
Helicase-Primase Inhibitors II-33
6. PRODUCT LAUNCHES AND APPROVALS II-34
Medivir Launches 'Xerese' Cream for Cold Sores in the US II-34
Actavis Launches Valaciclovir in Switzerland II-34
Matrix Labs Receives FDA Approval for Valacyclovir
Hydrochloride Tablets II-34
Ranbaxy Pharmaceuticals Launches Valacyclovir Hydrochloride
into US Market II-35
Sirion Therapeutics Secures US FDA Approval for ZirganTM 0.15% II-35
Meridian Life Science Introduces Herpes Simplex Virus Antigens II-35
7. RECENT INDUSTRY ACTIVITY II-36
Amgen Acquires BioVex II-36
Antigenics Changes Name to Agenus II-36
Clinigen Signs Agreement with AstraZeneca for Purchase of
Foscavir II-36
NanoViricides Inks R&D Deal with Dr. Ken S. Rosenthal's
Laboratory II-37
New American Therapeutics Purchases US Rights of Denavir II-37
GlaxoSmithKline Acquires Xeclear Marketing Rights from Medivir II-37
Bausch & Lomb Acquires Zirgan® Marketing Rights for the US Market II-37
Genocea In-Licenses HSV Patent Estate from University of
Washington II-38
Medivir Teams Up with Meda for Marketing Xerese in the US II-38
GSK and NanoBio Ink Licensing Deal for NB-001 II-38
Mymetics Takes Over Bestewil Holding II-38
Sanofi Pasteur Acquires Acambis II-39
Profectus Enters into an Assignment and License Deal with Wyeth II-39
8. FOCUS ON SELECT GLOBAL PLAYERS II-40
Agenus, Inc. (US) II-40
AiCuris GmbH & Co.KG (Germany) II-40
Astellas Pharma, Inc. (Japan) II-40
Clinigen Group (UK) II-41
Cytogenix, Inc. (US) II-41
Genocea Biosciences (US) II-41
GlaxoSmithKline Plc. (UK) II-42
Lumavita AG (Switzerland) II-42
NanoBio Corporation (US) II-43
NanoViricides, Inc. (US) II-43
Novartis International AG (Switzerland) II-43
Sanofi (France) II-44
Starpharma Holdings Limited (Australia) II-44
Vical (US) II-44
9. GLOBAL MARKET PERSPECTIVE II-46
Table 6: World Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market by Geographic Region -
US, Europe, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) II-46
Table 7: World Historic Review for Herpes Simplex Virus
Treatment Market by Geographic Region - US, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-47
Table 8: World 15-Year Perspective for Herpes Simplex Virus
Treatment Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Europe, and Rest of World Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-48
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Herpes Simplex Infection Increases in the US III-1
HSV Infections In Different Races III-1
Valtrex Dominates US HSV Prescription Market III-1
Table 9: Leading Drugs in US Herpes Therapeutics Market
(2011): Percentage Breakdown of New Prescriptions for
Valtrex, Acyclovir, Zovirax, Aldara, Denavir, and Famvir
(includes corresponding Graph/Chart) III-2
Product Launches III-2
Clinical Trials III-4
Strategic Corporate Developments III-5
Key Players III-7
B.Market Analytics III-10
Table 10: The US Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-10
Table 11: The US Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-11
2. EUROPE III-12
Market Analytics III-12
Table 12: European Recent Past, Current & Future Analysis
for Herpes Simplex Virus Treatment Market by Geographic
Region - France, Germany, Italy, UK, Spain, Russia & Rest of
Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-12
Table 13: European Historic Review for Herpes Simplex Virus
Treatment Market by Geographic Region - France, Germany,
Italy, UK, Spain, Russia & Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-13
Table 14: European 15-Year Perspective for Herpes Simplex
Virus Treatment Market by Geographic Region - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, UK,
Spain, Russia & Rest of Europe Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-14
2a. FRANCE III-15
A.Market Analysis III-15
Key Player III-15
B.Market Analytics III-16
Table 15: French Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-16
Table 16: French Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-17
2b. GERMANY III-18
A.Market Analysis III-18
Key Player III-18
B.Market Analytics III-19
Table 17: German Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-19
Table 18: German Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-20
2c. ITALY III-21
Market Analytics III-21
Table 19: Italian Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-21
Table 20: Italian Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-22
2d. THE UNITED KINGDOM III-23
A.Market Analysis III-23
Clinical Trials III-23
Strategic Corporate Developments III-23
Key Players III-24
B.Market Analytics III-26
Table 21: The UK Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-26
Table 22: The UK Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-27
2e. SPAIN III-28
Market Analytics III-28
Table 23: Spanish Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-28
Table 24: Spanish Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-29
2f. RUSSIA III-30
Market Analytics III-30
Table 25: Russian Recent Past, Current & Future Analysis for
Herpes Simplex Virus Treatment Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-30
Table 26: Russian Historic Review for Herpes Simplex Virus
Treatment Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-31
2g. REST OF EUROPE III-32
A.Market Analysis III-32
Product Launch III-32
Strategic Corporate Development III-32
Key Players III-32
B.Market Analytics III-34
Table 27: Rest of European Recent Past, Current & Future
Analysis for Herpes Simplex Virus Treatment Market with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) III-34
Table 28: Rest of European Historic Review for Herpes
Simplex Virus Treatment Market with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-35
3. REST OF WORLD III-36
A.Market Analysis III-36
Clinical Trial III-36
Key Players III-36
B.Market Analytics III-37
Table 29: Rest of World Recent Past, Current & Future
Analysis for Herpes Simplex Virus Treatment Market with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) III-37
Table 30: Rest of World Historic Review for Herpes Simplex
Virus Treatment Market with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-38
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 38 (including Divisions/Subsidiaries - 41)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 20
Canada 1
Japan 3
Europe 11
France 1
Germany 1
The United Kingdom 3
Rest of Europe 6
Asia-Pacific (Excluding Japan) 5
Latin America 1
------------------------------------------
To order this report:
Pathology Industry: Global Herpes Simplex Virus Treatment Industry
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article